Keyphrases
Acquired Resistance
100%
Apoptosis
25%
BRAF Inhibition
100%
BRAF Inhibitor (BRAFi)
75%
BRAF mutation
25%
BRAF-mutant Melanoma
100%
Cell Cycle Arrest
25%
Center Node
25%
Combination Therapy
25%
Cultured Cells
25%
Drug Resistance
50%
Efficient Strategy
25%
Immunohistochemistry
25%
In Vitro Experiment
25%
Inhibitor Combination
25%
Inhibitor Therapy
25%
Intracellular Signaling
25%
Mammalian Target of Rapamycin (mTOR)
100%
MAPK Inhibitors
25%
MEK Inhibitor (MEKi)
100%
Melanoma
100%
Melanoma Cells
25%
Mitogen-activated Protein Kinase
25%
MTOR Inhibitor
25%
MTORC1 Signaling
50%
NVP-BEZ235
50%
PDX Model
25%
Rapamycin
50%
Reverse Phase Protein Array
25%
Signaling Network
50%
Signaling Pathway
75%
Tumor
25%
Tumor Growth
25%
Western Blotting
25%
Xenograft Model
25%
Biochemistry, Genetics and Molecular Biology
Cell Culture
33%
Cell Cycle Arrest
33%
Drug Resistance
66%
Intracellular Signaling
33%
Mammalian Target of Rapamycin
66%
MEK Inhibitor
100%
Mitogen-Activated Protein Kinase
66%
mTOR Signaling
100%
Protein Microarray
33%
Rebound
33%
Signal Transduction
100%
Tumor Progression
33%
Western Blot
33%
Medicine and Dentistry
BEZ235
33%
Cell Culture
16%
Cell Cycle Arrest
16%
Cell Line
16%
Combination Therapy
16%
Drug Resistance
33%
Immunohistochemistry
16%
In Vitro
16%
Intracellular Signaling
16%
Mammalian Target of Rapamycin
16%
Mammalian Target of Rapamycin Inhibitor
16%
MEK Inhibitor
50%
Melanoma Cell
16%
Mitogen-Activated Protein Kinase
33%
mTOR Signaling
100%
Neoplasm
16%
Nodular Melanoma
100%
Programmed Cell Death
16%
Protein Microarray
16%
Rapamycin
33%
Rebound
16%
Signal Transduction
50%
Tumor Progression
16%
Western Blot
16%
Xenograft
16%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
14%
Dactolisib
28%
Drug Resistance
28%
Mammalian Target of Rapamycin Inhibitor
14%
Melanoma
100%
Mitogen Activated Protein Kinase Kinase Inhibitor
42%
Neoplasm
14%
Rapamycin
28%
Tumor Growth
14%
Western Blot
14%